Latest news with #Lawyers
Malaysian Reserve
2 days ago
- Business
- Malaysian Reserve
RXST Investors Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit
NEW YORK, July 28, 2025 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between November 7, 2024 and July 8, 2025, both dates inclusive (the 'Class Period'). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 22, 2025. So What: If you purchased RxSight securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the RxSight class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email case@ for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 22, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) RxSight was experiencing 'adoption challenges' and/or structural issues resulting in declines in sales and utilization; (2) defendants had overstated the demand for RxSight's products; (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (4) as a result of the foregoing, defendants' positive statements about RxSight's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the RxSight class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email case@ for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Kim, Rosen Law Firm, P.A.275 Madison Avenue, 40th FloorNew York, NY 10016Tel: (212) 686-1060Toll Free: (866) 767-3653Fax: (212) 202-3827case@
CTV News
16-07-2025
- Politics
- CTV News
First Nations leaders call to strike down bill to fast-track infrastructure
Video 'Absolute power corrupts absolutely': Lawyers representing nine First Nations call on governments to strike down Bill 5 in its entirety and key parts of Bill C-5.
Malaysian Reserve
15-07-2025
- Business
- Malaysian Reserve
CNC Investors Have Opportunity to Lead Centene Corporation Securities Fraud Lawsuit
NEW YORK, July 14, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Centene Corporation (NYSE: CNC) between December 12, 2024 and June 30, 2025, both dates inclusive (the 'Class Period'). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 8, 2025. So What: If you purchased Centene securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Centene class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email case@ for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, defendants throughout the Class Period provided investors with material information concerning Centene's expected revenue guidance and adjusted diluted EPS for the 2025 fiscal year. Defendants' statements included, among other things, confidence in Centene's enrollment and morbidity rates, as well as strong retention rates in Centene's Medicare business. According to the lawsuit, defendants provided these overwhelmingly positive statements to investors while simultaneously disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Centene's enrollment and morbidity rates. Such statements absent these material facts caused shareholders to purchase Centene's securities at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Centene class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email case@ for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@
Associated Press
08-07-2025
- Business
- Associated Press
From Product to Practice: What Lawyers Really Want From AI, According to MiAI Law CEO Laina Chan
SYDNEY, AUSTRALIA, July 8, 2025 / / -- MiAI Law is reshaping Legal AI Research by addressing what legal professionals truly need: trust, traceability, and legal reasoning—built from the ground up by a practicing barrister. In the latest interview from Xraised, 'From Product to Practice: What Lawyers Really Want From AI', award-winning barrister and MiAI Law CEO Laina Chan breaks down the gap between traditional legaltech tools and the real-world demands of lawyers. Rather than hype, Chan brings a grounded, legal-first approach to AI—offering a clear vision of how Legal AI Research should serve the legal profession. MiAI Law: The AI Built by a Barrister, Not Just Engineers Founded by Laina Chan, a practicing construction law barrister with over two decades at the bar, MiAI Law was developed with one question in mind: What do lawyers actually need from AI? 'It's not just about getting quick answers,' Chan says. 'Lawyers need responses they can trust—rooted in legal principles, backed by citations, and structured to match the way we think.' With a legal architecture designed by Chan herself, MiAI Law delivers fast, accurate, footnoted answers sourced from primary case law and legislation—removing the guesswork that plagues generic AI tools. Chan did not build MiAI Law to impress VCs. She built it because she was sick of legal tech that couldn't reason—and wasting hours doing case law the hard way. Most tools were fast but shallow, smart-sounding but legally useless. MiAI Law is different: it thinks like a lawyer because it was built by one, with legal reasoning, traceability, and primary sources at its core—not shortcuts. Real Legal AI Research, Not Just Flashy Tech Many AI tools fail lawyers by focusing on form over function. They sound smart but miss legal nuance. MiAI Law changes that. The platform reasons from first principles, traverses full legal databases, and ties every conclusion to a verifiable source. 'Generic models hallucinate. MiAI Law doesn't,' Chan explains. 'It's been trained to think like a barrister, not a chatbot.' In benchmark testing, MiAI Law answered 30 high-level legal questions in under two hours—research that previously took weeks of manual work. It's not about replacing lawyers. It's about giving them a competitive edge. What Lawyers Really Want From AI: Speed With Substance Chan highlights a key misconception: that lawyers simply want faster tools. In reality, MiAI Law focuses on transparency, accuracy, and efficiency—turning AI into a legal research partner, not a risk factor. Every MiAI Law report includes footnotes and direct hyperlinks to relevant cases or statutes, allowing lawyers to verify and explore results with full context. Whether they're in a mediation, drafting pleadings, or validating strategy, users know exactly where the information comes from. AI Is Not the Threat—It's the Ally Chan addresses the lingering fear that AI could replace legal professionals: 'AI won't take your job. But someone using AI effectively might,' she notes. 'I built MiAI Law to help myself—not replace myself.' Rather than automating legal judgment, MiAI Law frees up time so lawyers can focus on what truly matters: strategy, advocacy, and outcomes. It gives them the capacity to be sharper, faster, and better informed—without compromising ethics or quality. See the Interview, Explore the Future Watch the full conversation with Laina Chan and learn how MiAI Law is building the next generation of Legal AI Research: From Product to Practice: What Lawyers Really Want From AI. Learn more about MiAI Law's products and legal-first design: 🔗 Media Contact: Ethan Hunt [email protected] Gianmarco Giordaniello Xraised email us here Visit us on social media: LinkedIn Instagram X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Malaysian Reserve
27-06-2025
- Business
- Malaysian Reserve
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit
NEW YORK, June 27, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the 'Class Period'). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 25, 2025. So What: If you purchased Sarepta Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Sarepta class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email case@ for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 25, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) ELEVIDYS, a prescription gene therapy intended for certain patients being treated for Duchenne muscular dystrophy, posed significant safety risks to patients; (2) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (3) the severity of adverse events from ELEVIDYS treatment would cause Sarepta to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy's present and expanded approvals; and (4) as a result of the foregoing, Defendants materially misled with, and/or lacked a reasonable basis for, their positive statements. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Sarepta class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email case@ for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Kim, Rosen Law Firm, P.A.275 Madison Avenue, 40th FloorNew York, NY 10016Tel: (212) 686-1060Toll Free: (866) 767-3653Fax: (212) 202-3827case@
